NeOnc Technologies Holdings, Inc.NTHI
Key ratios
FCF / Sales
-52921.5%TTM
2025
-50912.4%2024
-5078.2%2023
-2667.0%
ROA
-635.0%TTM
2025
-1166.5%2024
-190.7%2023
-507.6%
Revenue growth
100.0%TTM
2025
-51.8%2024
17.8%2023
252.3%
Recent news
NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy
NeOnc Technologies and the Department of Health – Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration
NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026
NeOnc Strengthens Boardroom Firepower as Abu Dhabi Opens a New Path for Brain Cancer Drug Development
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
NeOnc Charting New Nasal Route to Treating Brain Cancer
NeOnc' Phase 2 Data Could Put Cancer on the Ropes
NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout
Track NTHI in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer